Rosemary Compound Shows Promise as Alzheimer’s Treatment

Select Language:

A natural compound found in common herbs like rosemary and sage may hold promise for future Alzheimer’s treatments. Researchers have developed a more stable version of this plant-derived substance, which has shown the ability to enhance memory and minimize brain damage in animal models of Alzheimer’s disease. While the research is still in its early phases, these findings have sparked optimism among scientists about the potential for safer, more effective therapies down the line.

This study was conducted by scientists at Scripps Research and published in the journal Antioxidants.

Alzheimer’s disease is the leading cause of dementia, a condition characterized by a decline in memory, thinking skills, language ability, and daily functioning. Over years, it progressively destroys brain cells, making it increasingly difficult for affected individuals to remember recent events, recognize loved ones, solve problems, or live independently. With millions worldwide impacted and numbers rising due to increased longevity, the quest for better treatments remains urgent.

Currently, most medications only help manage symptoms temporarily and do not halt the disease’s progression. Newer drugs aimed at removing harmful brain proteins show promise but often come with serious side effects and are not universally effective. As a result, researchers continue to explore various strategies for brain protection.

Historically, rosemary has been associated with memory and remembrance, even symbolized by William Shakespeare. Scientists have recently identified that rosemary and sage contain a natural compound called carnosic acid. This substance functions as both an antioxidant, protecting cells from damage, and an anti-inflammatory, reducing long-lasting tissue inflammation. Brain inflammation is increasingly recognized as a significant contributor to Alzheimer’s disease, as it damages neurons and weakens synapses—the tiny junctions between brain cells that facilitate communication vital for learning and memory.

Despite its potential benefits, carnosic acid faces a key challenge: it is highly unstable. It tends to break down rapidly when exposed to air or during storage, complicating efforts to develop it into a drug. To address this, the Scripps team engineered a new compound called diAcCA. This stable form remains intact during storage but converts back into active carnosic acid once ingested. After swallowing, diAcCA is processed in the digestive system, enters the bloodstream, and travels to the brain where it exerts its effects.

In tests using mice engineered to exhibit Alzheimer’s-like symptoms, diAcCA produced promising results. Treated animals performed significantly better on memory tests compared to untreated counterparts, with some approaching normal memory function. Brain analyses revealed increased connectivity between neurons, reduced inflammation, and lowered levels of amyloid-beta plaques and phosphorylated tau proteins—two hallmarks of Alzheimer’s pathology.

Interestingly, diAcCA also facilitated greater absorption of the active compound—about 20% more than direct intake of carnosic acid—meaning more of the therapeutic agent reaches the brain. Importantly, safety assessments showed no signs of toxicity, and the compound even appeared to lower inflammation in the digestive tract, hinting at additional health benefits.

Dr. Stuart Lipton, the lead researcher, noted that diAcCA’s main advantage lies in its targeted activation, primarily in inflamed areas of the brain. This selectivity could help shield healthy tissue from unnecessary exposure, reducing potential side effects. Because carnosic acid has a well-established safety record in humans, scientists are optimistic that the path to clinical trials might be quicker than for novel drugs.

Nonetheless, extensive testing in human subjects remains essential to confirm safety and effectiveness. Researchers also see potential for this compound to be studied in connection with other inflammation-related conditions, such as Parkinson’s disease, type 2 diabetes, and cardiovascular diseases.

Though it’s too early to suggest rosemary can prevent or cure Alzheimer’s, this research underscores how natural plant compounds can inspire innovative medicines. By combining traditional botanical benefits with modern drug technology, scientists are paving the way for new treatments that could better safeguard the aging brain.

For those interested in brain health, ongoing studies also explore links between vitamin D deficiency and Alzheimer’s, as well as possible benefits of oral cannabis extracts in reducing symptoms. Additional research examines how vitamin B9 deficiency correlates with increased dementia risk, and how flavonoid-rich diets could improve survival rates in Parkinson’s disease.